RxDoctor Payments Data

Sumit Duggal

Cardiovascular Disease · Frederick, MDNPI 1386806784

Payments from drug & device makers

$1,099in general payments, 2019–2025

Across 23 payments — averaging $47.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$812
  • Novartis$80
  • Amgen$47
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$44
  • Abbott$25
  • E.r. Squibb & Sons, L.L.C.$22
  • plus $70 from 4 others

What the payments were for

  • Travel & lodging$76469%
  • Food & beverage$33531%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,099 in reported general payments places this provider in the 40th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$941,841
Medicare patients
2,144
Services billed
7,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban438$564,059
XareltoRivaroxaban157$218,437
EntrestoSacubitril/Valsartan111$164,779
Repatha SureclickEvolocumab24$29,632
FarxigaDapagliflozin Propanediol15$24,816
MultaqDronedarone Hcl11$23,953
JardianceEmpagliflozin20$18,800
Metoprolol Succinate735$12,952
Atorvastatin Calcium635$10,694
Praluent PenAlirocumab11$10,199
Rosuvastatin Calcium309$8,294
Dabigatran EtexilateDabigatran Etexilate Mesylate19$6,863
Ezetimibe123$6,158
Amiodarone Hcl140$5,810
Nifedipine ErNifedipine119$4,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$19$218,437157 claims
NovartisEntresto$80$164,779111 claims
AstraZenecaFarxiga$14$24,81615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →